Omari Baruti's questions to Passage BIO (PASG) leadership • Q4 2022
Question
Omari Baruti from Goldman Sachs asked about the specific outputs Passage Bio is looking for in the early infantile high-dose GM1 cohort to justify pursuing registrational studies and whether there is any visibility on the potential registrational endpoint for GM1.
Answer
CEO Will Chou stated they are looking for two key outputs: durable decreases in GM1 ganglioside levels and measurable improvement in patient development. CMO Mark Forman added that the specific registrational endpoints will be defined following ongoing discussions with regulatory health authorities.